NEO241018C19000
- 0.05
- 0.000.00%
NeoGenomics Newsroom
Does NeoGenomics (NASDAQ:NEO) Have A Healthy Balance Sheet?
NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Trevi Therapeutics (TRVI) and DENTSPLY SIRONA (XRAY)
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Announces Target Price $18
NeoGenomics Hold Rating Maintained Amidst Ongoing Legal Challenges and MRD Assay Development Uncertainty
Needham Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $19
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Craig-Hallum Remains a Buy on NeoGenomics (NEO)
NeoGenomics Analyst Ratings
Benchmark Co. Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $18
Analysts Conflicted on These Healthcare Names: American Well (AMWL), Cogent Biosciences (COGT) and NeoGenomics (NEO)
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
Express News | Neogenomics Announces New Radar Technology and Resolution of Radar 1.0 Litigation
Express News | Natera: Seeks Full Remedies, After Patent Office Denied Neogenomics' Petition for 'inter Partes' Review Challenging Validity of '454 Patent
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of CtDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
NeoGenomics (NASDAQ:NEO Shareholders Incur Further Losses as Stock Declines 3.2% This Week, Taking Three-year Losses to 69%
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Express News | Neogenomics Inc : Piper Sandler Raises Target Price to $21 From $20